Can I increase my sulindac (150 mg twice daily) dose for fibromyalgia and generalized chronic pain?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Do Not Increase Sulindac Dose for Fibromyalgia

You should not increase your sulindac dose because NSAIDs are not effective for fibromyalgia pain and are specifically recommended against for this condition. 1, 2 You are already at the maximum recommended dose of 400 mg daily (150 mg twice daily = 300 mg/day is standard, with 400 mg/day being the absolute maximum), and increasing further would exceed FDA-approved dosing limits without providing benefit for your condition 3.

Why Sulindac Is Not Appropriate for Fibromyalgia

The 2022 VA/DoD guidelines for chronic multisymptom illness explicitly suggest against offering NSAIDs for chronic pain related to fibromyalgia 1. The 2017 EULAR fibromyalgia guidelines similarly provide a weak recommendation against NSAIDs, noting that two small trials showed no evidence of improved outcomes compared to placebo 2. This is because fibromyalgia involves abnormal central pain processing rather than peripheral inflammation—NSAIDs target inflammation that isn't the primary problem in your condition.

Maximum Dosing Considerations

According to FDA labeling, sulindac dosing is 3:

  • Standard dose for arthritis: 150 mg twice daily (300 mg/day)
  • Absolute maximum: 400 mg per day
  • Explicit warning: "Dosages above 400 mg per day are not recommended"

You're currently at 300 mg/day, which is already the standard therapeutic dose. The FDA label states to "use the lowest effective dose for the shortest duration" 3.

What You Should Use Instead

The most recent and highest-quality evidence supports these first-line medications for fibromyalgia pain 1, 4, 2:

First-Line Pharmacologic Options:

  • Duloxetine (SNRI): 30-60 mg daily, can increase to 60-120 mg daily—FDA-approved for fibromyalgia 4, 2
  • Milnacipran (SNRI): FDA-approved for fibromyalgia 4
  • Pregabalin: Starting 50 mg three times daily, increase to 100 mg three times daily (maximum 600 mg/day in divided doses)—FDA-approved for fibromyalgia 4, 2
  • Amitriptyline: 10-25 mg nightly, increase to 50-150 mg nightly (though evidence is limited and it's potentially inappropriate for those ≥65 years due to anticholinergic effects) 4

Non-Pharmacologic Options (Equally Important):

  • Cognitive-behavioral therapy: Suggested for fibromyalgia 1
  • Exercise programs: Suggested for fibromyalgia 1
  • Yoga or tai chi: Suggested for fibromyalgia 1
  • Manual acupuncture: Suggested as part of management 1

Critical Safety Concern

Long-term NSAID use (which you're currently doing) carries significant cardiovascular and gastrointestinal risks, particularly with chronic pain conditions 4. The 2022 CDC opioid guideline notes NSAIDs should be "used with caution, particularly in older persons and in patients with cardiovascular comorbidities, chronic renal failure, or previous gastrointestinal bleeding" 4.

Recommended Action Plan

  1. Do not increase sulindac dose—you're at maximum recommended dosing and it's ineffective for fibromyalgia
  2. Discuss with your provider transitioning to duloxetine or pregabalin—these are evidence-based, FDA-approved options
  3. Taper off sulindac gradually once an effective alternative is established
  4. Incorporate non-pharmacologic therapies (exercise, CBT) as these provide comparable or superior benefits to medications alone

The evidence is clear: continuing or increasing an ineffective medication that carries cardiovascular and GI risks makes no clinical sense when proven alternatives exist specifically for your condition.

Related Questions

What off‑label medications are recommended for an adult with fibromyalgia?
How should fibromyalgia be pharmacologically managed based on the dominant pain phenotype and co‑existing conditions?
Is there any newly FDA‑approved medication for the treatment of fibromyalgia pain?
Is Carafate (sucralfate) an appropriate treatment for fibromyalgia?
What are the most evidence‑based pharmacologic options for treating fibromyalgia, including recommended dosing and combination strategies?
What are the recommended doses of bupropion (Wellbutrin) for the sustained‑release, extended‑release, and immediate‑release formulations in adults?
Should a 35-year-old woman with hepatitis B surface antigen positivity, HBV DNA level of 76,000 IU/mL, normal alanine aminotransferase (ALT), and normal liver architecture be started on antiviral therapy now?
What is the most evidence‑based therapy for PD‑L1‑positive gallbladder cancer in patients who have progressed after first‑line gemcitabine‑cisplatin chemotherapy?
What are the possible causes of elevated jugular venous pressure?
Has the patient with PD‑L1‑positive gallbladder cancer already received all standard chemotherapy options, including gemcitabine‑cisplatin, FOLFOX, and other fluoropyrimidine‑ or irinotecan‑based regimens?
In a 66‑year‑old female with major depressive disorder (recurrent, moderate), generalized anxiety disorder, insomnia, dysarthria and cognitive deficits following cerebral infarction, who is taking escitalopram 5 mg daily, mirtazapine 15 mg at bedtime, trazodone 100 mg at bedtime, memantine 5 mg daily, and cholecalciferol 5000 IU daily, and reports persistent trouble sleeping after an ineffective trial of cognitive‑behavioral therapy, what safe pharmacologic intervention can be used to improve her sleep?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.